Does the media refer more to KURA or CPRX?

In the previous week, Kura Oncology and Kura Oncology both had 5 articles in the media. Catalyst Pharmaceuticals' average media sentiment score of 1.63 beat Kura Oncology's score of 0.85 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Catalyst Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer RLAY or KURA?

In the previous week, Relay Therapeutics and Relay Therapeutics both had 5 articles in the media. Kura Oncology's average media sentiment score of 0.85 beat Relay Therapeutics' score of 0.64 indicating that Kura Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kura Oncology 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor KURA or NAMS?

In the previous week, NewAmsterdam Pharma had 6 more articles in the media than Kura Oncology. MarketBeat recorded 11 mentions for NewAmsterdam Pharma and 5 mentions for Kura Oncology. NewAmsterdam Pharma's average media sentiment score of 1.18 beat Kura Oncology's score of 0.85 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DNLI or KURA?

In the previous week, Denali Therapeutics and Denali Therapeutics both had 5 articles in the media. Kura Oncology's average media sentiment score of 0.85 beat Denali Therapeutics' score of 0.71 indicating that Kura Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kura Oncology 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor KURA or ADPT?

In the previous week, Adaptive Biotechnologies had 3 more articles in the media than Kura Oncology. MarketBeat recorded 8 mentions for Adaptive Biotechnologies and 5 mentions for Kura Oncology. Adaptive Biotechnologies' average media sentiment score of 0.85 beat Kura Oncology's score of 0.85 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Kura Oncology (KURA) Competitors

$10.39 -0.06 (-0.57%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$10.45 +0.06 (+0.58%)

As of 07/24/2026 07:34 PM Eastern

Compare

KURA vs. CPRX, RLAY, NAMS, DNLI, and ADPT

Should you buy Kura Oncology stock or one of its competitors? MarketBeat compares Kura Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kura Oncology include Catalyst Pharmaceuticals (CPRX), Relay Therapeutics (RLAY), NewAmsterdam Pharma (NAMS), Denali Therapeutics (DNLI), and Adaptive Biotechnologies (ADPT). These companies are all part of the "pharmaceutical products" industry.

How does Kura Oncology compare to Catalyst Pharmaceuticals?

Kura Oncology (NASDAQ:KURA) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

In the previous week, Kura Oncology and Kura Oncology both had 5 articles in the media. Catalyst Pharmaceuticals' average media sentiment score of 1.63 beat Kura Oncology's score of 0.85 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Catalyst Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Kura Oncology has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

Catalyst Pharmaceuticals has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	13.67	-$278.67M	-$3.35	N/A
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10

79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 7.6% of Kura Oncology shares are owned by company insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Kura Oncology's net margin of -411.19%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-411.19%	-141.95%	-43.28%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

Kura Oncology presently has a consensus price target of $25.46, indicating a potential upside of 145.06%. Catalyst Pharmaceuticals has a consensus price target of $32.00, indicating a potential upside of 1.62%. Given Kura Oncology's stronger consensus rating and higher possible upside, equities research analysts plainly believe Kura Oncology is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

Summary

Catalyst Pharmaceuticals beats Kura Oncology on 12 of the 16 factors compared between the two stocks.

How does Kura Oncology compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Kura Oncology (NASDAQ:KURA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

Relay Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -411.19%. Relay Therapeutics' return on equity of -43.94% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-43.94%	-40.11%
Kura Oncology	-411.19%	-141.95%	-43.28%

Relay Therapeutics has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

Relay Therapeutics currently has a consensus target price of $24.92, suggesting a potential upside of 35.12%. Kura Oncology has a consensus target price of $25.46, suggesting a potential upside of 145.06%. Given Kura Oncology's higher possible upside, analysts plainly believe Kura Oncology is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.86
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

In the previous week, Relay Therapeutics and Relay Therapeutics both had 5 articles in the media. Kura Oncology's average media sentiment score of 0.85 beat Relay Therapeutics' score of 0.64 indicating that Kura Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kura Oncology	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.0% of Relay Therapeutics shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by insiders. Comparatively, 7.6% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Relay Therapeutics has higher earnings, but lower revenue than Kura Oncology. Relay Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$10.68M	330.91	-$276.48M	-$1.57	N/A
Kura Oncology	$67.48M	13.67	-$278.67M	-$3.35	N/A

Summary

Relay Therapeutics beats Kura Oncology on 10 of the 15 factors compared between the two stocks.

How does Kura Oncology compare to NewAmsterdam Pharma?

Kura Oncology (NASDAQ:KURA) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Kura Oncology currently has a consensus price target of $25.46, indicating a potential upside of 145.06%. NewAmsterdam Pharma has a consensus price target of $49.42, indicating a potential upside of 66.72%. Given Kura Oncology's higher possible upside, equities research analysts plainly believe Kura Oncology is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

Kura Oncology has a net margin of -411.19% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-411.19%	-141.95%	-43.28%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

In the previous week, NewAmsterdam Pharma had 6 more articles in the media than Kura Oncology. MarketBeat recorded 11 mentions for NewAmsterdam Pharma and 5 mentions for Kura Oncology. NewAmsterdam Pharma's average media sentiment score of 1.18 beat Kura Oncology's score of 0.85 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kura Oncology has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.08, suggesting that its stock price is 92% less volatile than the broader market.

NewAmsterdam Pharma has lower revenue, but higher earnings than Kura Oncology. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	13.67	-$278.67M	-$3.35	N/A
NewAmsterdam Pharma	$22.57M	153.56	-$203.82M	-$1.79	N/A

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 7.6% of Kura Oncology shares are owned by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

NewAmsterdam Pharma beats Kura Oncology on 11 of the 16 factors compared between the two stocks.

How does Kura Oncology compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Kura Oncology (NASDAQ:KURA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

In the previous week, Denali Therapeutics and Denali Therapeutics both had 5 articles in the media. Kura Oncology's average media sentiment score of 0.85 beat Denali Therapeutics' score of 0.71 indicating that Kura Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kura Oncology	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

92.9% of Denali Therapeutics shares are owned by institutional investors. 9.7% of Denali Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Kura Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Denali Therapeutics presently has a consensus price target of $35.17, suggesting a potential upside of 52.17%. Kura Oncology has a consensus price target of $25.46, suggesting a potential upside of 145.06%. Given Kura Oncology's higher probable upside, analysts clearly believe Kura Oncology is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Denali Therapeutics has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

Denali Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -411.19%. Denali Therapeutics' return on equity of -52.20% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Kura Oncology	-411.19%	-141.95%	-43.28%

Kura Oncology has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	11.10	-$512.54M	-$2.88	N/A
Kura Oncology	$67.48M	13.67	-$278.67M	-$3.35	N/A

Summary

Denali Therapeutics beats Kura Oncology on 10 of the 16 factors compared between the two stocks.

How does Kura Oncology compare to Adaptive Biotechnologies?

Kura Oncology (NASDAQ:KURA) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

Kura Oncology currently has a consensus price target of $25.46, indicating a potential upside of 145.06%. Adaptive Biotechnologies has a consensus price target of $20.83, indicating a potential downside of 6.45%. Given Kura Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Kura Oncology is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Kura Oncology has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.07, meaning that its stock price is 107% more volatile than the broader market.

Adaptive Biotechnologies has a net margin of -16.82% compared to Kura Oncology's net margin of -411.19%. Adaptive Biotechnologies' return on equity of -40.06% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-411.19%	-141.95%	-43.28%
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%

Adaptive Biotechnologies has higher revenue and earnings than Kura Oncology. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	13.67	-$278.67M	-$3.35	N/A
Adaptive Biotechnologies	$276.98M	12.87	-$59.50M	-$0.33	N/A

In the previous week, Adaptive Biotechnologies had 3 more articles in the media than Kura Oncology. MarketBeat recorded 8 mentions for Adaptive Biotechnologies and 5 mentions for Kura Oncology. Adaptive Biotechnologies' average media sentiment score of 0.85 beat Kura Oncology's score of 0.85 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adaptive Biotechnologies	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 7.6% of Kura Oncology shares are owned by company insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Adaptive Biotechnologies beats Kura Oncology on 10 of the 16 factors compared between the two stocks.

Get Kura Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KURA vs. The Competition

Export

Metric	Kura Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$927.69M	$3.67B	$6.86B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-3.10	21.48	27.14	23.64
Price / Sales	13.67	169.92	517.01	89.03
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	5.20	7.88	10.28	6.07
Net Income	-$278.67M	$23.86M	$3.60B	$331.99M
7 Day Performance	-4.33%	-3.82%	-1.27%	-0.63%
1 Month Performance	0.29%	-2.61%	-0.37%	-2.00%
1 Year Performance	66.77%	32.79%	18.30%	13.62%

Kura Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KURA Kura Oncology	3.4702 of 5 stars	$10.39 -0.6%	$25.46 +145.1%	+60.6%	$927.69M	$67.48M	N/A	130	News Coverage Positive News
CPRX Catalyst Pharmaceuticals	4.4145 of 5 stars	$31.49 flat	$32.00 +1.6%	N/A	$3.86B	$596.96M	18.10	80	News Coverage Short Interest Decrease
RLAY Relay Therapeutics	3.0133 of 5 stars	$19.18 -3.7%	$24.17 +26.0%	+401.1%	$3.81B	$15.35M	N/A	330	News Coverage Analyst Forecast
NAMS NewAmsterdam Pharma	2.9051 of 5 stars	$29.67 -6.3%	$49.42 +66.6%	+26.7%	$3.70B	$22.50M	N/A	4	News Coverage
DNLI Denali Therapeutics	2.6048 of 5 stars	$22.90 -1.7%	$35.08 +53.2%	+61.5%	$3.70B	$330.53M	N/A	430	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KURA) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kura Oncology (KURA) Competitors

KURA vs. CPRX, RLAY, NAMS, DNLI, and ADPT

How does Kura Oncology compare to Catalyst Pharmaceuticals?

Summary

How does Kura Oncology compare to Relay Therapeutics?

Summary

How does Kura Oncology compare to NewAmsterdam Pharma?

Summary

How does Kura Oncology compare to Denali Therapeutics?

Summary

How does Kura Oncology compare to Adaptive Biotechnologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KURA vs. The Competition

Kura Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kura Oncology (KURA) Competitors

KURA vs. CPRX, RLAY, NAMS, DNLI, and ADPT

How does Kura Oncology compare to Catalyst Pharmaceuticals?

Does the media refer more to KURA or CPRX?

Which has more volatility & risk, KURA or CPRX?

Which has higher earnings and valuation, KURA or CPRX?

Do institutionals and insiders have more ownership in KURA or CPRX?

Is KURA or CPRX more profitable?

Do analysts rate KURA or CPRX?

Summary

How does Kura Oncology compare to Relay Therapeutics?

Is RLAY or KURA more profitable?

Which has more volatility & risk, RLAY or KURA?

Do analysts prefer RLAY or KURA?

Does the media prefer RLAY or KURA?

Do insiders & institutionals hold more shares of RLAY or KURA?

Which has higher valuation and earnings, RLAY or KURA?

Summary

How does Kura Oncology compare to NewAmsterdam Pharma?

Do analysts rate KURA or NAMS?

Is KURA or NAMS more profitable?

Does the media favor KURA or NAMS?

Which has more volatility and risk, KURA or NAMS?

Which has higher valuation and earnings, KURA or NAMS?

Do institutionals & insiders believe in KURA or NAMS?

Summary

How does Kura Oncology compare to Denali Therapeutics?

Does the media refer more to DNLI or KURA?

Do institutionals and insiders hold more shares of DNLI or KURA?

Do analysts prefer DNLI or KURA?

Which has more volatility and risk, DNLI or KURA?

Is DNLI or KURA more profitable?

Which has better valuation & earnings, DNLI or KURA?

Summary

How does Kura Oncology compare to Adaptive Biotechnologies?

Do analysts prefer KURA or ADPT?

Which has more risk and volatility, KURA or ADPT?

Is KURA or ADPT more profitable?

Which has better valuation and earnings, KURA or ADPT?

Does the media favor KURA or ADPT?

Do insiders & institutionals have more ownership in KURA or ADPT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KURA vs. The Competition

Kura Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools